WAVE Life Sciences Ltd.
WVE
$6.79
-$0.28-3.96%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 38.25M | 17.25M | 7.61M | 8.70M | 9.18M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 38.25M | 17.25M | 7.61M | 8.70M | 9.18M |
| Cost of Revenue | 47.44M | 52.81M | 45.87M | 43.47M | 40.62M |
| Gross Profit | -9.19M | -35.57M | -38.27M | -34.77M | -31.45M |
| SG&A Expenses | 22.10M | 20.90M | 18.09M | 17.99M | 18.36M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 69.54M | 73.71M | 63.96M | 61.46M | 58.98M |
| Operating Income | -31.30M | -56.47M | -56.35M | -52.76M | -49.80M |
| Income Before Tax | -26.09M | -53.18M | -53.85M | -50.47M | -46.88M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -26.09M | -53.18M | -53.85M | -50.47M | -46.88M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -26.09M | -53.18M | -53.85M | -50.47M | -46.88M |
| EBIT | -31.30M | -56.47M | -56.35M | -52.76M | -49.80M |
| EBITDA | -30.46M | -55.62M | -55.50M | -51.89M | -48.93M |
| EPS Basic | -0.13 | -0.30 | -0.32 | -0.31 | -0.29 |
| Normalized Basic EPS | -0.08 | -0.18 | -0.20 | -0.19 | -0.18 |
| EPS Diluted | -0.13 | -0.30 | -0.32 | -0.31 | -0.29 |
| Normalized Diluted EPS | -0.08 | -0.18 | -0.20 | -0.19 | -0.18 |
| Average Basic Shares Outstanding | 200.17M | 180.15M | 167.74M | 163.99M | 162.57M |
| Average Diluted Shares Outstanding | 200.17M | 180.15M | 167.74M | 163.99M | 162.57M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |